Lise Lotte Gluud, EASD 2021: Effect of Subcutaneous Semaglutide on Features of the Metabolic Syndrome in Patients with Non-alcoholic Steatohepatitis
touchENDOCRINOLOGY caught up with Prof Lise Lotte Gluud (Copenhagen University Hospital, Hvidovre, Denmark) virtually during the EASD Annual Meeting 2021 conference to discuss her study on the effect of subcutaneous semaglutide on features of the metabolic syndrome in patients with non-alcoholic steatohepatitis.
Questions
1. Could you give us a brief overview of the association of non-alcoholic steatohepatitis and metabolic syndrome? (0:17-00:49)
2. Could you tell us a little about the Phase 2 study investigating semaglutide in the treatment of NASH and its primary outcomes? (00:49-01:28)
3. What was the objective of the current analysis? (01:28-02:21)
4. What were the findings in different patient subgroups in terms of the metabolic endpoints studied? (02:21-02:52)
5. What evidence suggests that the findings are a direct effect of semaglutide rather than a consequence of weight loss? (02:52-03:35)
Speaker Disclosure: Lise Lotte Gluud has been an advisory board member for Novo Nordisk and received research fees from Novo Nordisk, Gilead, Sobi and Alexion.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Louise Taylor.
Filmed in coverage of the EASD Annual Meeting 2021
